Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2021-12-10 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Trading Plan under PIT
Regulatory Filings Classification · 100% confidence The document is an intimation filed under Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. It discloses the sale of equity shares by a promoter entity (Growel Remedies Limited) in the open market. The document includes a Form-C disclosure as required by SEBI for insider trading compliance. It is a regulatory compliance filing related to insider trading disclosures and share transactions by promoters. There are no financial statements, management discussion, or earnings data. The document is not an annual report, earnings release, or any other financial report type. It is a regulatory filing notifying the stock exchanges and the public about insider trading activity. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-12-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a notification under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the outcome of a meeting with investors/analysts. It mentions that the Investor Presentation referred to during the meeting has already been uploaded on the company's website and stock exchange websites. The document itself does not contain the presentation or detailed financial data but is an announcement about the meeting and the availability of the presentation. Given the nature of the content, this fits the category of an Investor Presentation announcement. However, since the actual presentation is not included but only referenced, and the document is relatively short (1872 characters), it is best classified as an Investor Presentation (IP) filing type, as it is a disclosure about the presentation to investors.
2021-12-06 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation for Shivalik Rasayan Ltd, including company vision, business overview, group structure, leadership team, product portfolio, R&D and manufacturing facilities, and commercial strategy. It contains no financial statements, regulatory filings, voting results, or legal proceedings. It is not an annual or quarterly report, audit report, earnings release, or any regulatory filing. The content is typical of an investor or corporate presentation aimed at providing an overview of the company, its products, strategy, and management to investors or stakeholders. Therefore, the appropriate classification is Investor Presentation (IP). The document length (over 12,000 characters) and detailed content support this classification with high confidence.
2021-12-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing about a scheduled meeting with investors and analysts, specifically an analyst meet via video conferencing. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a meeting schedule rather than a report or transcript of the meeting. It does not contain financial data, detailed presentations, or minutes of the meeting. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about an upcoming event and does not qualify as an Investor Presentation (IP) or Call Transcript (CT). The document length is short (1540 characters), supporting that it is an announcement rather than a full report or transcript.
2021-12-03 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Medicamen Biotech Limited to stock exchanges regarding the publication of un-audited financial results for the quarter and half year ended September 30, 2021. It references compliance with SEBI regulations and includes financial data such as earnings per share and equity share capital. The document mentions that the results were approved by the Board of Directors and published in newspapers. The presence of detailed financial figures and the reference to a limited review report by statutory auditors indicate this is a financial report for a period shorter than a full fiscal year. Therefore, this document is an Interim / Quarterly Report (IR). H1 2022
2021-11-08 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides details of related party transactions on a consolidated basis for the half year ended September 30, 2021. The document includes names and designations of key management personnel, transaction details with related parties, balances outstanding, and key management personnel compensation. The document length is 3685 characters, which is relatively short and appears to be a regulatory disclosure rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory filing disclosing related party transactions as required by SEBI regulations. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-11-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.